Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;60(3):335-346.
doi: 10.1007/s12275-022-1608-z. Epub 2022 Jan 28.

Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2

Chulwoo Kim  1 , Jae-Deog Kim  2   3 , Sang-Uk Seo  4   5
Affiliations
Review

Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2

Chulwoo Kim et al. J Microbiol. 2022 Mar.

Abstract

The global spread of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has provoked an urgent need for prophylactic measures. Several innovative vaccine platforms have been introduced and billions of vaccine doses have been administered worldwide. To enable the creation of safer and more effective vaccines, additional platforms are under development. These include the use of nanoparticle (NP) and virus-like particle (VLP) technology. NP vaccines utilize self-assembling scaffold structures designed to load the entire spike protein or receptor-binding domain of SARS-CoV-2 in a trimeric configuration. In contrast, VLP vaccines are genetically modified recombinant viruses that are considered safe, as they are generally replication-defective. Furthermore, VLPs have indigenous immunogenic potential due to their microbial origin. Importantly, NP and VLP vaccines have shown stronger immunogenicity with greater protection by mimicking the physicochemical characteristics of SARS-CoV-2. The study of NP- and VLP-based coronavirus vaccines will help ensure the development of rapid-response technology against SARS-CoV-2 variants and future coronavirus pandemics.

Keywords: COVID-19; SARS-CoV-2; nanoparticle; vaccine; virus-like particle.

PubMed Disclaimer

References

    1. Abbott RK, Lee JH, Menis S, Skog P, Rossi M, Ota T, Kulp DW, Bhullar D, Kalyuzhniy O, Havenar-Daughton C, et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity. 2018;48:133–146. doi: 10.1016/j.immuni.2017.11.023. - DOI - PMC - PubMed
    1. Al-Omari A, Rabaan AA, Salih S, Al-Tawfiq JA, Memish ZA. MERS coronavirus outbreak: implications for emerging viral infections. Diagn. Microbiol. Infect. Dis. 2019;93:265–285. doi: 10.1016/j.diagmicrobio.2018.10.011. - DOI - PMC - PubMed
    1. Alharbi NK, Qasim I, Almasoud A, Aljami HA, Alenazi MW, Alhafufi A, Aldibasi OS, Hashem AM, Kasem S, Albrahim R, et al. Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels. Sci. Rep. 2019;9:16292. doi: 10.1038/s41598-019-52730-4. - DOI - PMC - PubMed
    1. Andersson AC, Buldun CM, Pattinson DJ, Draper SJ, Howarth M. SnoopLigase peptide-peptide conjugation enables modular vaccine assembly. Sci. Rep. 2019;9:4625. doi: 10.1038/s41598-019-40985-w. - DOI - PMC - PubMed
    1. Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594:253–258. doi: 10.1038/s41586-021-03530-2. - DOI - PubMed

Supplementary concepts